Single-Use Technologies: Challenges and Solutions

Since their increased popularisation from the mid-1990s, single- and limited-use technologies (collectively SUTs) have changed the field of biomanufacturing. This has been driven partly by the heavy growth of the pharma market, from $162 billion in 2014 to around $270...

7 years ago
Bioprocess,Biomanufacturing,CMC,News

Single-Use Technologies: Challenges and Solutions

Since their increased popularisation from the mid-1990s, single- and limited-use technologies (collectively SUTs) have changed the field of biomanufacturing. This has been driven partly by the heavy growth of the pharma market, from $162 billion in 2014 to around $270...

7 years ago

The Abbvie-Allergan Deal: A Matter of Distrust?

Compared to the merger announcement itself, the industry reaction to the $63 billion Abbvie buyout of Allergan, announced this June, was no big surprise. Abbvie, seeking to replace its now-ageing blockbuster drug Humira, was the only suitor for the Botox...

7 years ago
Pharmacovigilance,News

The Abbvie-Allergan Deal: A Matter of Distrust?

Compared to the merger announcement itself, the industry reaction to the $63 billion Abbvie buyout of Allergan, announced this June, was no big surprise. Abbvie, seeking to replace its now-ageing blockbuster drug Humira, was the only suitor for the Botox...

7 years ago

Cancer Drugs Could be Hitting Wrong Targets

Current cancer drugs may be hitting the wrong protein targets, a study has found, giving a possible explanation for the low success rates of those drugs during their early stages.  The study, recently published in Science Translational Medicine journal and...

7 years ago
Oncology,Biology,News

Cancer Drugs Could be Hitting Wrong Targets

Current cancer drugs may be hitting the wrong protein targets, a study has found, giving a possible explanation for the low success rates of those drugs during their early stages.  The study, recently published in Science Translational Medicine journal and...

7 years ago

Google – The New Pharmaceutical Regulator?

Last Friday, Google stated in a press release that it would no longer be accepting advertisements for “speculative and experimental medical treatments”, including most stem cell or gene therapies, after observing unscrupulous companies taking advantage of patients through offers of...

7 years ago
Bioprocess,Regulatory Affairs,News

Google – The New Pharmaceutical Regulator?

Last Friday, Google stated in a press release that it would no longer be accepting advertisements for “speculative and experimental medical treatments”, including most stem cell or gene therapies, after observing unscrupulous companies taking advantage of patients through offers of...

7 years ago

Proventa’s Weekly Round-up – 7/10/19

Providing expert advice to C-Level Executives creating a tailor made, end to end solution from concept to execution.

7 years ago
Weekly Roundups

Proventa’s Weekly Round-up – 7/10/19

Providing expert advice to C-Level Executives creating a tailor made, end to end solution from concept to execution.

7 years ago
Previous Page Showing 323 out of 323
Working With us

Interested?
Reserve your space